postoperative cognitive dysfunction

01月14日的《热心肠日报》，我们解读了 10 篇文献，关注：限时进食，自身免疫病，强化食品，术后认知障碍，PUFA，坚果，维生素K1，素食，抑郁，食品政策。 Cell 子刊：限时进食的减肥效果（综述） Cell Metabolism——[29] ① 限时进食（TRE）通常是指将进食时间限制在4、6、8或10小时内，进食期间无需计算食物摄入量；② 12项TRE随机试验中，5项存在高偏倚风险，未来需更多高质量随机对照试验；③ TRE可在2-12个月内使肥胖症患者体重减轻3%-5%，减少脂肪和内脏脂肪，还可改善血压、空腹胰岛素和胰岛素抵抗；④ TRE可降低成人2型糖尿病患者的体重、LDL、血糖、胰岛素抵抗和糖化血红蛋白，改善血脂和胰岛素；⑤ TRE可轻微减轻多囊卵巢综合征患者的体重，改善雄激素指标。 【主编评语】 限时饮食（TRE）已经成为一种流行的治疗肥胖的策略。TRE包括将进食时间限制在每天4-10小时，其余时间禁食（14-20小时禁食）。在进食窗口期，个人不需要刻意监测食物摄入量，但通常能产生200-550千卡/日的能量赤字。TRE的流行很可能是因为它简单，而且它不需要人们计算卡路里来减肥。近期发表于Cell Metabolism的一篇综述总结了TRE对体重和代谢危险因素的随机临床试验的现有证据，此外还讨论了TRE在不同人群中的疗效，包括肥胖、2型糖尿病和多囊卵巢综合征患者。（@注册营养师陈彬林） 【原文信息】 Time-restricted eating: Watching the clock to treat obesity 2024-01-03, doi: 10.1016/j.cmet.2023.12.004 中科大Nature子刊：禁食可激活神经元调节T细胞，抑制小鼠自身免疫性疾病 Nature Neuroscience——[25] ① 通过病毒注射探究能量缺乏对儿茶酚胺能神经元（VLM-CA）活性影响，发现促食欲VLM-CA会诱导T细胞再分配；② 利用化学遗传学激活VLM-CA可阻止实验性自身免疫性脑脊髓炎发生和发展，改善大脑炎症和损伤；③ 去除VLM-CA可逆转空腹介导的T细胞分布，这些神经元激活以CXCR4/CXCL12轴突依赖方式驱动T细胞到骨髓，与刺激皮质酮分泌的神经回路有关；④ 与空腹类似，持续激活VLM-CA可抑制自身免疫小鼠模型T细胞活化增殖和细胞因子产生，缓解疾病症状。 【主编评语】 禁食影响免疫细胞的分布和功能，并发挥强大的免疫抑制作用。然而，禁食调节免疫的机制仍不清楚。近日，中国科学技术大学占成研究团队在Nature neuroscience发表最新研究，通过动物实验发现大脑脑干腹外侧延髓核（VLM）中响应饥饿刺激的儿茶酚胺能神经元（简称VLM-CA），能够调节T细胞归巢，并抑制自身免疫疾病，值得关注。（@九卿臣） 【原文信息】 Fasting-activated ventrolateral medulla neurons regulate T cell homing and suppress autoimmune disease in mice 2024-01-05, doi: 10.1038/s41593-023-01543-w Nature子刊：生物强化对缓解微量营养素缺乏的贡献（观点） Nature Food——[23.2] ① 从技术上讲，生物强化包括三种策略：农艺生物强化、通过育种进行生物强化、生物技术生物强化；② 食品营养强化计划的普遍成功导致生物强化改善微量营养素缺乏没有得到积极研究；③ 生物强化作物中关键微量营养素如维生素D3原/维生素D3、维生素B12和铁，以满足新的营养统计需求；④ 将生物强化扩大到水果和蔬菜可能是通过饮食提供广泛微量营养素的最佳途径；⑤ 将生物强化融入全球食物系统，可帮助克服隐性饥饿、改善营养和实现可持续农业。 【主编评语】 生物强化最早于20世纪90年代初提出，作为一种低成本、可持续的战略，旨在提高主食农作物的矿物质和维生素含量，以解决微量营养素营养不良问题。Nature Food最新观点文章，总结生物强化如何融入全球粮食系统，并对缓解微量营养素缺乏的贡献。（@RZN） 【原文信息】 Biofortification’s contribution to mitigating micronutrient deficiencies 2024-01-02, doi: 10.1038/s43016-023-00905-8 高脂饮食加剧术后认知功能障碍 Brain Behavior and Immunity——[15.1] ① 在老年大鼠中，高脂饮食和手术的结合导致了情境记忆和线索恐惧记忆的持续缺陷；② 在年轻的成年大鼠中，高脂饮食手术仅引起线索恐惧记忆缺陷；③ 单独使用高脂饮食会导致持续的杏仁核依赖性记忆缺陷；④ 高脂饮食会增强手术后的神经炎症反应；⑤ Toll样受体4拮抗剂可预防高脂饮食和手术引起的记忆障碍和海马神经炎症；⑥ 膳食DHA补充剂可预防高脂饮食和手术引起的神经炎症和记忆缺陷。 【主编评语】 术后认知功能障碍（POCD）是指手术后不久出现的神经认知功能突然下降，并持续数周至数月，增加了痴呆症诊断的风险。高龄、肥胖以及与高脂饮食相关的合并症（例如糖尿病和高血压）已被确定为POCD的危险因素，但潜在机制仍不清楚。Brain Behavior and Immunity最新研究工作表明高脂饮食以TLR4依赖性方式增加雄性大鼠手术后出现持续性POCD相关记忆障碍的风险，而通过膳食DHA补充剂可以减轻持续性POCD的发展。（@RZN） 【原文信息】 Post-operative cognitive dysfunction is exacerbated by high-fat diet via TLR4 and prevented by dietary DHA supplementation 2023-12-23, doi: 10.1016/j.bbi.2023.12.028 Nature子刊：机体利用多不饱和脂肪酸与脂质从头合成相关 Nature Communications——[16.6] ① 脂肪酸合成酶（FASN）是脂质从头合成(DNL)的关键酶，它在很大程度上决定了小鼠和人类饮食中多不饱和脂肪酸（PUFA）的利用；② 抑制FASN联合补充PUFA降低了高脂饮食喂养小鼠肝脏的三酰甘油（TAG）；③ 从机制上来说，抑制FASN通过溶血磷脂酰胆碱转运蛋白——主要促进因子超家族成员2a（MFSD2A）和二酯酰甘油酰基转移酶2（DGAT2）依赖的PUFA掺入TAG从而引起更高的PUFA利用。 【主编评语】 饮食中的多不饱和脂肪酸（PUFA）因其对健康的益处而越来越受到人们的认可，而内源性脂肪酸的大量产生——一种称为脂质从头合成（DNL）的过程——与代谢疾病密切相关。近期发表于Nature Communications的一项研究发现，补充PUFA的健康结局可能取决于内源性DNL的程度，将补充PUFA和抑制脂肪酸合成酶（FASN）结合起来可能是针对代谢性疾病如非酒精性脂肪肝的一种有希望的方法。（@注册营养师陈彬林） 【原文信息】 Fatty acid synthesis suppresses dietary polyunsaturated fatty acid use 2024-01-02, doi: 10.1038/s41467-023-44364-y 不同种类坚果和花生对特定血脂参数有何影响？（荟萃分析） Critical Reviews in Food Science and Nutrition——[10.2] ① 通过分析76项随机对照试验，评估六种坚果对总胆固醇、低密度脂蛋白（LDL-c）、甘油三酯（TG）和高密度脂蛋白（HDL-c）的影响并对其排名；② 开心果、杏仁、核桃总胆固醇，腰果、核桃和杏仁LDL-c，榛子和核桃TG显著降低，花生HDL-c水平显著升高；③ 降低总胆固醇最有效的坚果类型是开心果、降低LDL-c的是腰果、降低TG的是榛子，提高HDL-c水平的是花生；④ 每一种坚果对某些参数表现出显著积极影响，特定类型坚果对特定血脂表现出增强的优势。 【主编评语】 坚果和花生通过调节血脂水平显示出保护心脏的作用，尽管有大量的科学证据，但仍然不确定所食用的坚果类型是否会影响这些变化。近日，研究人员在Critical Reviews in Food Science and Nutrition发表最新研究，通过分析76项随机对照试验，通过荟萃分析发现降低总胆固醇最有效的坚果类型是开心果、降低LDL-c的是腰果、降低TG的是榛子，提高HDL-c水平的是花生，这些结果支持使用个性化的营养策略来解决和预防血脂异常，值得关注。（@九卿臣） 【原文信息】 Can different types of tree nuts and peanuts induce varied effects on specific blood lipid parameters? A systematic review and network meta-analysis 2023-12-28, doi: 10.1080/10408398.2023.2296559 膳食维生素K1或可降低主动脉瓣狭窄发生率 Arteriosclerosis, Thrombosis, and Vascular Biology——[8.7] ① 纳入50至64岁的参与者，基线时完成一份192项食物频率问卷，以此评估维生素K1的习惯性摄入量；② 55545名参与者中，被随访时间最长为21.5年，其中1085人被诊断为主动脉瓣狭窄，615人被确定为主动脉狭窄且随后出现并发症；③ 与最低五分之一的参与者相比，维生素K1摄入量最高的五分之一参与者患主动脉狭窄的风险降低23%，主动脉狭窄及其后并发症的风险降低27%。 【主编评语】 小叶钙化有助于主动脉瓣狭窄的发展和进展。维生素K激活血管钙化抑制剂，并可能调节炎症和骨骼骨丢失。Arteriosclerosis, Thrombosis, and Vascular Biology近期发表的文章，探索较高的维生素K1饮食摄入量是否与较低的主动脉狭窄发生率有关。结果显示，摄入大量富含维生素K1的食物可降低主动脉狭窄的发生率，降低主动脉狭窄及其并发症的风险。（@章台柳） 【原文信息】 Dietary Vitamin K1 Intake and Incident Aortic Valve Stenosis 2023-12-28, doi: 10.1161/ATVBAHA.123.320271 纯素食者和素食者，钙摄入量是否充足？（荟萃分析） Critical Reviews in Food Science and Nutrition——[10.2] ① 植物性饮食越来越受欢迎，但以植物为基础的饮食可能不能确保微量营养素的充足供应，特别是钙；② 共纳入74项研究，包括7356名纯素食者、51940名素食者和107581名杂食者；③ 纯素食者钙摄入量显著低于素食者和杂食者，而素食者和杂食者的钙摄入量无显著差异，不同研究间异质性较高；④ 杂食者与纯素食者或素食者间血清钙无显著差异，杂食者的尿钙显著高于素食者；⑤ 纯素食者的钙摄入量低于素食者和杂食者，提示有必要监测纯素食者的钙状态。 【主编评语】 植物性饮食是以摄取植物性食材为主要饮食来源的饮食法，但以植物为基础的饮食可能不能确保微量营养素的充足供应，特别是钙。近日，雷根斯堡大学研究人员在Critical Reviews in Food Science and Nutrition发表最新研究，开展一项荟萃分析共纳入74项研究，包括7356名纯素食者、51940名素食者和107581名杂食者，发现纯素食者的钙摄入量低于素食者和杂食者，提示有必要监测纯素食者的钙状态，值得关注。（@九卿臣） 【原文信息】 Calcium intake in vegan and vegetarian diets: A systematic review and Meta-analysis 2022-06-06, doi: 10.1080/10408398.2022.2084027 饮食干预可改善代谢疾病患者的抑郁 Advances in Nutrition——[9.3] ① 纳入13项对代谢疾病患者（2型糖尿病、高脂血症、高血压和/或超重/肥胖）进行饮食干预，且评估抑郁和/或焦虑的随机对照临床试验；② 荟萃分析模型中发现，抑郁评分有所改善，包括所有饮食干预和低热量饮食；③ 仅采用等热量饮食干预对抑郁评分没有改善；④ 任何饮食干预对焦虑评分都没有显著影响；⑤ 在患有代谢疾病的成年人中，所有的饮食干预和低热量饮食都能改善抑郁，但不能改善焦虑。 【主编评语】 有代谢疾病的人患抑郁症和焦虑症的风险更高。Advances in Nutrition近期发表的文章，通过系统综述和荟萃分析发现，包括低热量饮食在内的饮食干预措施可以在代谢疾病患者的抑郁症管理中发挥重要作用。（@章台柳） 【原文信息】 Diet overall and hypocaloric diets are associated with improvements in depression but not anxiety in people with metabolic conditions: A systematic review and meta-analysis 2024-01-05, doi: 10.1016/j.advnut.2024.100169 JAMA子刊：快餐店菜单标明食品热量会影响消费者选择吗？ JAMA Network Open——[13.8] ① 研究纳入2329个餐厅，共474份菜单，其中94.3%的餐厅来自加利福尼亚；② 双重差分模型j结果显示，与对照组相比，消费者在有菜单标签的餐厅每次购买的卡路里降低约24.7%；③ 对于营养素的选择结果与卡路里结果一致；④ 在幅度和方向上，全加利福尼亚州的结果均一致，但是在加利福尼亚之外，两者并无关联；⑤ 菜单标签的结果依据商品种类和取样时间的不同而有差异，其中选择墨西哥玉米卷的减少最多，时间上早餐卡路里摄入降低最多。 【主编评语】 美国餐厅在2008年就进行了菜单标签的使用，但是这些菜单标签是否会影响消费者选择，尤其是卡路里，还一直不明确。本文基于2007-2014年间的餐厅追踪数据，探究了其背后的相关性。研究结果显示，基于3-24个月的追踪结果，餐厅菜单标签可以降低消费者卡路里购买，且依据商品种类和取样时间的不同而有差异。（@Bingbing） 【原文信息】 Menu Labeling and Calories Purchased in Restaurants in a US National Fast Food Chain 2023-12-15, doi: 10.1001/jamanetworkopen.2023.46851 感谢本期日报的创作者：orchid，九卿臣，RZN，注册营养师陈彬林，章台柳，Jenny，Bingbing 点击阅读过去10天的日报： 01-13 | 多文聚焦：新方法新技术，助菌群研究更上一层楼 01-12 | 高分Cell子刊：郑啸/郝海平和吴浩等在肠脑轴和营养研究中各有新斩获 01-11 | Nature锐评：推动菌群研究全球化，功在千秋 01-10 | 多文聚焦：“不良”细菌祸害肠道的十八般武艺 01-09 | 《自然·综述》详解：炎症性肠病的“潜伏期” 01-08 | NEJM重磅：少喝酒如何影响癌症风险？ 01-07 | 人工智能火热，ChatGPT能否取代营养师？ 01-06 | 国内团队Nature子刊：用益生菌改善功能性消化不良 01-05 | 今日Science：新策略！减轻菌群相关的癌症免疫治疗副作用 01-04 | 傅静远等Nature突破：在遗传互作层面揭示血型与肠菌的密切关系

PALO ALTO, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a Notice of Allowance for United States (US) patent application number 17/721,106 entitled “Method of Treating Dupuytren’s disease Using a Pre-filled Syringe”, which includes claims relating to the use of a citrate-free formulation of 40mg in 0.4mL of adalimumab to be injected into nodules of early-stage Dupuytren’s disease every 3 months over a period of 12 months using a syringe with a 25 gauge needle. This reflects the dosage and method used in the RIDD trial led by Professor Nanchahal and his colleagues at the University of Oxford, the results of which were published in The Lancet Rheumatology. A Notice of Allowance is issued after the USPTO makes the determination that a patent should be granted from an application. A patent from the recently allowed application is expected to be issued in the coming months. The issued patent would have a term that expires no earlier than in 2037. “Current treatments for Dupuytren’s disease are largely limited to patients with finger contractures of late-stage disease. There is a pressing need for an effective therapy for patients with early-stage disease to prevent or delay disease progression. We believe that treatment with intranodular injections of adalimumab has the potential to achieve this,” said Professor Sir Marc Feldmann, co-chairman of 180 Life Sciences. Dr. James Woody, CEO of 180 Life Sciences, stated, “This allowance by the US Patent Office, and the expected formal patent, represent an important addition to our extensive patent estate on the use of anti-tumor necrosis factor (TNF) for the treatment of Dupuytren’s disease, which we hope in the future may be able to apply to a range of fibrotic disorders and postoperative cognitive decline. The patent relating to the allowance will represent another important step towards our overall strategy for advancing the use of adalimumab for early-stage Dupuytren’s disease”. With the addition of this potential patent, the patent portfolio of 180 Life Sciences will have twelve issued patents and twelve pending patent applications within the US. Outside of the US, assuming the EU as a single jurisdiction and including the UK, there are an additional twelve issued patents and 21 pending patent applications. About 180 Life Sciences Corp. 180 Life Sciences Corp. is a clinical-stage biotechnology company driving ground-breaking studies into clinical programs which are seeking to address major unmet medical needs. The Company’s focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). Forward-Looking Statements This press release includes “forward-looking statements”, including information about management’s view of the Company’s future expectations, plans and prospects, within the safe harbor provisions provided under federal securities laws, including under The Private Securities Litigation Reform Act of 1995 (the “Act”). Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, risks regarding whether the administrative processes required for the issuance of a patent as indicated in the Notice of Allowance will be completed in a timely manner or at all, whether the patent, if issued as indicated in the notice of allowance, will provide sufficient protection and market exclusivity for the Company, whether any patents held by the Company may be challenged, invalidated, infringed or circumvented by third parties; events that could interfere with the continued validity or enforceability of a patent; the Company’s ability generally to maintain adequate patent protection and successfully enforce patent claims against third parties; the timing of, outcome of, and results of, clinical trials; timing of our planned marketing authorization application (MAA) submission to the UK Medicines and Healthcare products Regulatory Agency (MHRA), our ability to obtain approval and acceptance thereof, the willingness of MHRA to review such MAA, and our ability to address outstanding comments and questions from the MHRA; statements about the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the uncertainties associated with the clinical development and regulatory approval of 180 Life Sciences’ drug candidates, including potential delays in the enrollment and completion of clinical trials, closures of such trials prior to enrolling sufficient participants in connection therewith; issues raised by the U.S. Food and Drug Administration (FDA) and MHRA; the ability of the Company to persuade MHRA that chosen endpoints do not require further validation; timing to complete required studies and trials, and timing to obtain governmental approvals; the accuracy of simulations and the ability to reproduce the outcome of such simulations in real world trials; 180 Life Sciences’ reliance on third parties to conduct its clinical trials, enroll patients, and manufacture its preclinical and clinical drug supplies; the ability to come to mutually agreeable terms with such third parties and partners, and the terms of such agreements; estimates of patient populations for 180 Life Sciences planned products; unexpected adverse side effects or inadequate therapeutic efficacy of drug candidates that could limit approval and/or commercialization, or that could result in recalls or product liability claims; 180 Life Sciences’ ability to fully comply with numerous federal, state and local laws and regulatory requirements, as well as rules and regulations outside the United States, that apply to its product development activities; the timing of filing, the timing of governmental review, and outcome of, planned Investigational New Drug (IND) applications for drug candidates; current negative operating cash flows and a need for additional funding to finance our operating plans; the terms of any further financing, which may be highly dilutive and may include onerous terms, increases in interest rates which may make borrowing more expensive and increased inflation which may negatively affect costs, expenses and returns; statements relating to expectations regarding future agreements relating to the supply of materials and license and commercialization of products; the availability and cost of materials required for trials; the risk that initial drug results are not predictive of future results or will not be able to be replicated in clinical trials or that such drugs selected for clinical development will not be successful; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market and economic conditions; our ability to produce acceptable batches of future products in sufficient quantities; unexpected manufacturing defects; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; expectations with respect to future performance, growth and anticipated acquisitions; the continued listing of the Company’s securities on The NASDAQ Stock Market; expectations regarding the capitalization, resources and ownership structure of the Company; expectations with respect to future performance, growth and anticipated acquisitions; the ability of the Company to execute its plans to develop and market new drug products and the timing and costs of these development programs; estimates of the size of the markets for its potential drug products; the outcome of current litigation involving the Company; potential future litigation involving the Company or the validity or enforceability of the intellectual property of the Company; global economic conditions; geopolitical events and regulatory changes; the expectations, development plans and anticipated timelines for the Company’s drug candidates, pipeline and programs, including collaborations with third parties; access to additional financing, and the potential lack of such financing; and the Company’s ability to raise funding in the future and the terms of such funding; and the effect of rising interest rates and inflation, and economic downturns and recessions. These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange Commission, including, but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks, and including the Annual Report on Form 10-K for the year ended December 31, 2021, and Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, and future SEC filings. These reports and filings are available at and are available for download, free of charge, soon after such reports are filed with or furnished to the SEC, on the “Investors”—“SEC Filings”—“All SEC Filings” page of our website at All subsequent written and oral forward-looking statements concerning the Company, the results of the Company’s clinical trial results and studies or other matters and attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, including the forward-looking statements included in this press release, which are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as otherwise provided by law. Investors: Jason Assad Director of IR 180 Life Sciences Corp Jassad@180lifesciences.com

Simultaneous Use of Masimo O3® Regional Oximetry, NomoLine® Capnography, SedLine® Brain Function Monitoring, and rainbow® Pulse CO-Oximetry Helped Clinicians Determine that Maintaining Higher End-tidal Carbon Dioxide (EtCO2) Improved Cerebral Oxygenation, Leading to Improved Outcomes NEUCHATEL, Switzerland--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced the findings of a prospective, single-blinded, randomized controlled study published in the Journal of Anesthesia & Intensive Care Medicine in which Dr. Mona Mohamed Mogahed and colleagues at Tanta University in Tanta, Egypt and The King Fahd General Hospital in Jeddah, Saudi Arabia, sought to evaluate the impact of varying ventilation strategies on the cerebral oxygenation of patients undergoing video-assisted thoracoscopic surgery (VATS). To monitor the variety of physiological parameters needed to undertake such an evaluation, they turned to the multi-modal Masimo Root® patient monitoring and connectivity platform, which is designed to allow clinicians to streamline their ability to keep track of numerous modalities, simultaneously, using a single, intuitive monitor. The technologies involved included O3® regional oximetry, capnography with NomoLine® sampling lines, SedLine® brain function monitoring, and multiple rainbow® Pulse CO-Oximetry measurements. Using Root and Masimo monitoring technologies, the researchers were able to determine that maintaining higher end-tidal carbon dioxide (EtCO2) improved baseline regional cerebral oxygenation (rSO2), with impacts on early postoperative cognitive function that included improvements in Aldrete scores and mini mental status exam (MMSE) scores.1 This press release features multimedia. View the full release here: Masimo Root® (Graphic: Business Wire) Noting the increased risk of hypoxemia during one-lung ventilation (OLV) as part of VATS, which can lead to postoperative neurocognitive dysfunctions, the authors hypothesized that increasing EtCO2 could be a “convenient and powerful” way to manage cerebral desaturation during the surgery. They enrolled 70 patients, ages 18-65, undergoing elective VATS requiring OLV, between September 2021 and September 2022 at The King Fahd General Hospital, Jeddah. All patients were operated on by the same surgical team. The patients were randomly divided into two groups: in the first, EtCO2 was maintained at 32-38 mmHg (group I) and in the second, at 39-45 mmHg (group II). During the procedure, monitored parameters included oxygen saturation (Masimo SET® SpO2), heart rate (HR), and noninvasive hemoglobin (Masimo SpHb®) via an RD rainbow SET® fingertip sensor; EtCO2 via capnometer and NomoLine sampling line; noninvasive blood pressure (NIBP), body temperature, and rSO2 via O3 near-infrared spectroscopy (NIRS) sensors monitoring both brain hemispheres; and Masimo Patient State Index (PSi™), a processed EEG parameter used to help clinicians maintain appropriate sedation, via SedLine. Outcomes included Aldrete scores and MMSE scores assessed at 3 and 24 hours after surgery. The researchers found that the percentage of change in rSO2 differed significantly between groups (p < 0.05), on both sides of the brain, with the higher values, over time, in Group II, in direct relation with the higher EtCO2 maintained in that group. In the right hemisphere, the difference became significant at the fourth time interval [T4] at which rSO2 was recorded, p = 0.0012, and maintained significance for the remainder of surgery [T4-T13], p < 0.001. In the left hemisphere, the difference became significant at T2, p = 0.09, and remained significant [T3-13], p < 0.001. Aldrete scores were significantly higher in Group II upon arrival at the post-anesthesia care unit (PACU) (p = 0.013) and 15 minutes after arrival (p = 0.03), then became comparable. MMSE scores were significantly higher in Group II 3 hours after surgery (p = 0.0009), but not at 24 hours after surgery. The researchers concluded, “Adjusting the ventilator parameters to develop EtCO2 of 39-45 mmHg improved cerebral oxygenation more than EtCO2 of 32-38 mmHg, that play[s] a protective role in the brain, causing significant impact on the early postoperative cognitive function in patients with OLV undergoing VATS.” Regarding the use of Masimo Root and associated monitoring technologies, they noted that they “preferred using it as it can display several clinical measurements [at] the same time, such as HR, BP, temperature, SpO2, EtCO2, PSi, and rSO2.” @Masimo | #Masimo About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.2 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,3 improve CCHD screening in newborns,4 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.5-8 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,9 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll.10 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7®, Radius PPG®, and Radius VSM™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing portfolio of health and wellness solutions includes Radius Tº® and the Masimo W1™ watch. Additional information about Masimo and its products may be found at . Published clinical studies on Masimo products can be found at . ORi, RPVi, and Radius VSM have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium. References Mogahed MM, Alnoamani TS, Elkahwagy MS. The Ventilatory Influence on Cerebral Oxygenation in Patients Undergoing Video Assisted Thoracoscopic Surgery. J Anest & Inten Care Med. 12(3). December 2022. DOI: 10.19080/JAICM.202212.555837. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at . Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696. Estimate: Masimo data on file. . Forward-Looking Statements This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo Root®, O3®, NomoLine®, SedLine®, rainbow®, RD rainbow SET®, SpHb®, SET®, and PSi™. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo Root, O3, NomoLine, SedLine, rainbow®, RD rainbow SET, SpHb, SET®, and PSi, contribute to positive clinical outcomes and patient safety; risks that the researchers’ conclusions and findings may be inaccurate; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws. View source version on businesswire.com: Contacts Media Contact: Masimo Evan Lamb 949-396-3376 elamb@masimo.com Source: Masimo Smart Multimedia Gallery Photo Masimo Root® (Graphic: Business Wire) Logo View this news release and multimedia online at: